Abstract: The present disclosure provides methods of evaluating therapeutic or prophylactic agents or other medical technologies for patients with Parkinson's disease being treated with L-DOPA or L-DOPA-related compounds or dopamine agonists. Specifically, it provides a method of evaluating a therapeutic or prophylactic agent or other medical technology for a patient with Parkinson's disease who is being treated with L-DOPA or an L-DOPA-related compound or a dopamine agonist, including A) a step of obtaining ocular information of the patient, and B) a step of calculating an estimated effective amount or effective level of the therapeutic or prophylactic agent or other medical technology from the ocular information.

Abstract: A cylinder body is sandwiched between a front head and a rear head. A high pressure port is formed in the front head. A roller of a piston is configured such that top and bottom end surfaces thereof have different widths. The roller is arranged such that one of the top and bottom end surfaces having a larger width faces the front head 7.

Abstract: A cylinder body 2 is sandwiched between a front head 7 and a rear head 8 and a high pressure port 10 is formed in the front head 7. A roller 3 of a piston 5 is configured such that top and bottom end surfaces thereof have different widths. The roller 3 is arranged such that one of the end surfaces having a larger width faces the front head 7.